Article · 4 May 2026
ArticlePublished 30 Apr 2025
Antitumor Effects of Troglitazone and Its Association with Peroxisome Proliferator-Activated Receptor Gamma Activation in FaDu Human Hypopharyngeal Carcinoma Cells
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Troglitazone, originally approved by the Food and Drug Administration for the management of type II diabetes, was later withdrawn due to its severe hepatotoxic effects. In an effort to repurpose Troglitazone, we investigated its potential antitumor effects on FaDu human hypopharyngeal carcinoma cells. Our study found that Troglitazone induced cell cycle arrest at the G2/M phase, which was accompanied by a reduction in key cyclins and cyclin-dependent kinase regulators. Simultaneously, Troglitazone upregulated negative regulators such as p21CIP1/WAF1 and p27KIP1. Furthermore, Troglitazone activated key apoptotic caspases, leading to the cleavage of poly (ADP-ribose) polymerase. These apoptotic responses were mediated through the intrinsic pathway, involving the regulation of both anti-apoptotic and pro-apoptotic factors. Notably, Troglitazone-induced apoptosis was linked to a marked increase in the expr ession of peroxisome proliferator-activated receptor gamma, and this effect was partially reversed by GW9662, a peroxisome proliferator-activated receptor gamma antagonist. In conclusion, our findings suggest that Troglitazone exerts its antitumor effects through peroxisome proliferator-activated receptor gamma activation, making it a promising candidate for repurposing as a therapeutic agent for human hypo pharyngeal car cinoma.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Indian Journal of Pharmaceutical Sciences.
Article · 21 Apr 2026
In silico molecular docking analysis of bioactive compounds from Kappaphycus alvarezii and Gracilaria debilis against BRCA1 protein
Article · 11 Mar 2026
Trimethoprim and Sulfamethoxazole-Loaded Nanoparticles Coated With Chitosan for Intranasal Delivery to Treat Cerebral Toxoplasmosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalIndian Journal of Pharmaceutical Sciences
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Thu Do”
- BylineArticles whose byline prints “T T Loan”
- BylineArticles whose byline prints “T D Le”
- BylineArticles whose byline prints “P D Vu”
- BylineArticles whose byline prints “Hoon Yoo”